Compare Global Payments Inc (GPN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Natera Inc. Common Stock — how do they compare? Global Payments Inc trades at $80.89 (market cap $21.67B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.6× Global Payments Inc's market cap, and Global Payments Inc pays a 1.22% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Natera Inc. Common Stock for 0 Days on average.
| GPN | NTRA | |
|---|---|---|
Market Cap | $21.67B | $57.03B |
Volume | 1,851,678 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $94.83 | $425.64 |
52-Week Low | $62.47 | $179.42 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.81B | $56.18B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $80.89, down 1.43% on the day, with a neutral technical outlook despite recent earnings beats. The company shows strong revenue growth momentum with Q2 2026 EPS of $3.46 beating estimates, while maintaining a P/E of 38.81 and P/B below 1.0. Recent developments include the Genius platform rollout and Worldpay integration driving business expansion.
The stock offers 27% upside to the $102.75 consensus price target with strong analyst support (59% buy ratings), though negative net income margin and rising debt-to-asset ratio to 41.57% present execution risks. Key catalysts include continued Genius adoption while competition and cost pressures remain headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
